Label-free Cell-based Assay for Peptide-receptor Interaction Characterisation

Jul 1, 2014

Both the drug development process and fundamental studies of mechanisms underlying biological interactions require analytical methods that mimic the in vivo situation as much as possible. But this can be approached by using label-free cell-based assays. Davide Proverbio and Teodor Aastrup of Attana AB, and Jana Valnohova, Shane C. Wright and Gunnar Schulte of Karolinska Institutet, present a new cell-based assay that they developed for characterising interactions between peptides and their target receptors in a label-free environment. ...

Read More

Current Perspective on TBI

Jul 1, 2014

Dr Adrian Harel of Medicortex conveys the urgency of developing mitigating therapeutics for the secondary and long-term damaging effects of TBI. His article makes clear that in order to ensure effectiveness, new treatment options must be multifaceted and include neuroprotective, neurorestorative and anti-inflammatory agents. Soon the day may come when brain injuries of children, seniors, athletes, service personnel, and others, will be treated in much the same way injuries in other parts of the body are currently being treated. ...

Read More

Ready for Battle: How Preclinical Development Brings New Vaccines to the War on Disease

Jul 1, 2014

Few medical advances have made as large an impact on world health as vaccines. Yet the battle isn’t over. As new infectious diseases emerge, as old ones grow resistant, and as our understanding of human immune response increases, researchers are developing novel vaccines, creative delivery tools, and innovative approaches. Stephene Rose of MPI Research explains why the preclinical realm is especially important to identifying and advancing the most promising candidates that could save innumerable lives. ...

Read More